232 related articles for article (PubMed ID: 34737197)
1. SAM-Competitive PRMT5 Inhibitor PF-06939999 Demonstrates Antitumor Activity in Splicing Dysregulated NSCLC with Decreased Liability of Drug Resistance.
Jensen-Pergakes K; Tatlock J; Maegley KA; McAlpine IJ; McTigue M; Xie T; Dillon CP; Wang Y; Yamazaki S; Spiegel N; Shi M; Nemeth A; Miller N; Hendrickson E; Lam H; Sherrill J; Chung CY; McMillan EA; Bryant SK; Palde P; Braganza J; Brooun A; Deng YL; Goshtasbi V; Kephart SE; Kumpf RA; Liu W; Patman RL; Rui E; Scales S; Tran-Dube M; Wang F; Wythes M; Paul TA
Mol Cancer Ther; 2022 Jan; 21(1):3-15. PubMed ID: 34737197
[TBL] [Abstract][Full Text] [Related]
2. A phase I study to evaluate the safety, pharmacokinetics, and pharmacodynamics of PF-06939999 (PRMT5 inhibitor) in patients with selected advanced or metastatic tumors with high incidence of splicing factor gene mutations.
Rodon J; Rodriguez E; Maitland ML; Tsai FY; Socinski MA; Berlin JD; Thomas JS; Al Baghdadi T; Wang IM; Guo C; Golmakani M; Clark LN; Gazdoiu M; Li M; Tolcher AW
ESMO Open; 2024 Apr; 9(4):102961. PubMed ID: 38640748
[TBL] [Abstract][Full Text] [Related]
3. Cellular localization of protein arginine methyltransferase-5 correlates with grade of lung tumors.
Shilo K; Wu X; Sharma S; Welliver M; Duan W; Villalona-Calero M; Fukuoka J; Sif S; Baiocchi R; Hitchcock CL; Zhao W; Otterson GA
Diagn Pathol; 2013 Dec; 8():201. PubMed ID: 24326178
[TBL] [Abstract][Full Text] [Related]
4. Interaction assessments of the first S-adenosylmethionine competitive inhibitor and the essential interacting partner methylosome protein 50 with protein arginine methyltransferase 5 by combined computational methods.
Zhu K; Jiang CS; Hu J; Liu X; Yan X; Tao H; Luo C; Zhang H
Biochem Biophys Res Commun; 2018 Jan; 495(1):721-727. PubMed ID: 29154828
[TBL] [Abstract][Full Text] [Related]
5. PRMT5 promotes chemotherapy-induced neuroendocrine differentiation in NSCLC.
Shen Q; Liu Y; Deng X; Hu CD
Thorac Cancer; 2023 Jun; 14(18):1764-1773. PubMed ID: 37140020
[TBL] [Abstract][Full Text] [Related]
6. Structure-Based Discovery and Biological Assays of a Novel PRMT5 Inhibitor for Non-Small Cell Lung Cancer.
Chen Y; Zhang M; Wu A; Yao X; Wang Q
Molecules; 2022 Nov; 27(21):. PubMed ID: 36364261
[TBL] [Abstract][Full Text] [Related]
7. Circular RNA PRMT5 confers cisplatin-resistance via miR-4458/REV3L axis in non-small-cell lung cancer.
Pang J; Ye L; Zhao D; Zhao D; Chen Q
Cell Biol Int; 2020 Dec; 44(12):2416-2426. PubMed ID: 32808744
[TBL] [Abstract][Full Text] [Related]
8. Development of an AlphaLISA high throughput technique to screen for small molecule inhibitors targeting protein arginine methyltransferases.
Prabhu L; Chen L; Wei H; Demir Ö; Safa A; Zeng L; Amaro RE; O'Neil BH; Zhang ZY; Lu T
Mol Biosyst; 2017 Nov; 13(12):2509-2520. PubMed ID: 29099132
[TBL] [Abstract][Full Text] [Related]
9. Discovery and Pharmacological Characterization of JNJ-64619178, a Novel Small-Molecule Inhibitor of PRMT5 with Potent Antitumor Activity.
Brehmer D; Beke L; Wu T; Millar HJ; Moy C; Sun W; Mannens G; Pande V; Boeckx A; van Heerde E; Nys T; Gustin EM; Verbist B; Zhou L; Fan Y; Bhargava V; Safabakhsh P; Vinken P; Verhulst T; Gilbert A; Rai S; Graubert TA; Pastore F; Fiore D; Gu J; Johnson A; Philippar U; Morschhäuser B; Walker D; De Lange D; Keersmaekers V; Viellevoye M; Diels G; Schepens W; Thuring JW; Meerpoel L; Packman K; Lorenzi MV; Laquerre S
Mol Cancer Ther; 2021 Dec; 20(12):2317-2328. PubMed ID: 34583982
[TBL] [Abstract][Full Text] [Related]
10. PRMT5 Selective Inhibitor Enhances Therapeutic Efficacy of Cisplatin in Lung Cancer Cells.
Bajbouj K; Ramakrishnan RK; Saber-Ayad M; Omar HA; Saheb Sharif-Askari N; Shafarin J; Elmoselhi AB; Ihmaid A; AlHaj Ali S; Alalool A; Abdullah R; Hamid Q
Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34200178
[TBL] [Abstract][Full Text] [Related]
11. Circular RNA circ-PRMT5 facilitates non-small cell lung cancer proliferation through upregulating EZH2 via sponging miR-377/382/498.
Wang Y; Li Y; He H; Wang F
Gene; 2019 Dec; 720():144099. PubMed ID: 31479715
[TBL] [Abstract][Full Text] [Related]
12. Myelocytomatosis-Protein Arginine N-Methyltransferase 5 Axis Defines the Tumorigenesis and Immune Response in Hepatocellular Carcinoma.
Luo Y; Gao Y; Liu W; Yang Y; Jiang J; Wang Y; Tang W; Yang S; Sun L; Cai J; Guo X; Takahashi S; Krausz KW; Qu A; Chen L; Xie C; Gonzalez FJ
Hepatology; 2021 Oct; 74(4):1932-1951. PubMed ID: 33896016
[TBL] [Abstract][Full Text] [Related]
13. Combined inhibition of MTAP and MAT2a mimics synthetic lethality in tumor models via PRMT5 inhibition.
Bedard GT; Gilaj N; Peregrina K; Brew I; Tosti E; Shaffer K; Tyler PC; Edelmann W; Augenlicht LH; Schramm VL
J Biol Chem; 2024 Jan; 300(1):105492. PubMed ID: 38000655
[TBL] [Abstract][Full Text] [Related]
14. The protein arginine methyltransferase PRMT5 confers therapeutic resistance to mTOR inhibition in glioblastoma.
Holmes B; Benavides-Serrato A; Saunders JT; Landon KA; Schreck AJ; Nishimura RN; Gera J
J Neurooncol; 2019 Oct; 145(1):11-22. PubMed ID: 31473880
[TBL] [Abstract][Full Text] [Related]
15. Role of protein arginine methyltransferase 5 in group 3 (MYC-driven) Medulloblastoma.
Chaturvedi NK; Mahapatra S; Kesherwani V; Kling MJ; Shukla M; Ray S; Kanchan R; Perumal N; McGuire TR; Sharp JG; Joshi SS; Coulter DW
BMC Cancer; 2019 Nov; 19(1):1056. PubMed ID: 31694585
[TBL] [Abstract][Full Text] [Related]
16. Validation of protein arginine methyltransferase 5 (PRMT5) as a candidate therapeutic target in the spontaneous canine model of non-Hodgkin lymphoma.
Sloan SL; Renaldo KA; Long M; Chung JH; Courtney LE; Shilo K; Youssef Y; Schlotter S; Brown F; Klamer BG; Zhang X; Yilmaz AS; Ozer HG; Valli VE; Vaddi K; Scherle P; Alinari L; Kisseberth WC; Baiocchi RA
PLoS One; 2021; 16(5):e0250839. PubMed ID: 33989303
[TBL] [Abstract][Full Text] [Related]
17. Protein arginine methyltransferase 5: a potential cancer therapeutic target.
Yuan Y; Nie H
Cell Oncol (Dordr); 2021 Feb; 44(1):33-44. PubMed ID: 33469838
[TBL] [Abstract][Full Text] [Related]
18. PRMT5 inhibition disrupts splicing and stemness in glioblastoma.
Sachamitr P; Ho JC; Ciamponi FE; Ba-Alawi W; Coutinho FJ; Guilhamon P; Kushida MM; Cavalli FMG; Lee L; Rastegar N; Vu V; Sánchez-Osuna M; Coulombe-Huntington J; Kanshin E; Whetstone H; Durand M; Thibault P; Hart K; Mangos M; Veyhl J; Chen W; Tran N; Duong BC; Aman AM; Che X; Lan X; Whitley O; Zaslaver O; Barsyte-Lovejoy D; Richards LM; Restall I; Caudy A; Röst HL; Bonday ZQ; Bernstein M; Das S; Cusimano MD; Spears J; Bader GD; Pugh TJ; Tyers M; Lupien M; Haibe-Kains B; Artee Luchman H; Weiss S; Massirer KB; Prinos P; Arrowsmith CH; Dirks PB
Nat Commun; 2021 Feb; 12(1):979. PubMed ID: 33579912
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and Activity of Triazole-Adenosine Analogs as Protein Arginine Methyltransferase 5 Inhibitors.
Brown T; Cao M; Zheng YG
Molecules; 2022 Jun; 27(12):. PubMed ID: 35744905
[TBL] [Abstract][Full Text] [Related]
20. Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma.
AbuHammad S; Cullinane C; Martin C; Bacolas Z; Ward T; Chen H; Slater A; Ardley K; Kirby L; Chan KT; Brajanovski N; Smith LK; Rao AD; Lelliott EJ; Kleinschmidt M; Vergara IA; Papenfuss AT; Lau P; Ghosh P; Haupt S; Haupt Y; Sanij E; Poortinga G; Pearson RB; Falk H; Curtis DJ; Stupple P; Devlin M; Street I; Davies MA; McArthur GA; Sheppard KE
Proc Natl Acad Sci U S A; 2019 Sep; 116(36):17990-18000. PubMed ID: 31439820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
